Apollo Hospitals Q4 Review - Business Restructuring For Potential Value Unlocking: ICICI Direct
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Direct Report
Apollo Hospitals Enterprises Ltd.'s Q4 FY21 revenues came in at Rs 2868 crore (our estimate: Rs 2857.7 crore).
They are not comparable YoY due to restructuring of the retail pharmacy business to pharmacy distribution (post demerger).
On the other hand, the hospital segment grew 10.1% YoY to Rs 1443 crore versus our estimate of Rs 1490 crore.
Pharmacy distribution segment revenues came in at Rs 1118.7 crore.
Ebitda margins improved 135 basis points YoY to 14.4% mainly due to lower staff cost, which likely stems from restructuring of retail pharmacy to pharmacy distribution.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.